Medifron DBT Co. Ltd Total Liabilities

Latest as of September 2025: ₩86.61 Billion KRW ≈ $58.70 Million USD

Medifron DBT Co. Ltd total liabilities. Based on the latest financial reports, Medifron DBT Co. Ltd (065650) has total liabilities worth ₩86.61 Billion KRW (≈ $58.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Medifron DBT Co. Ltd to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Medifron DBT Co. Ltd (2014–2024)

Total liabilities of Medifron DBT Co. Ltd from 2014 to 2024. This chart illustrates how Medifron DBT Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Medifron DBT Co. Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.

Medifron DBT Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Medifron DBT Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
COINSILIUM GROUP LTD F:5CT	Germany	€161.47K
Scibase AB ST:SCIB	Sweden	Skr45.58 Million
Optimi Health Corp. Common Shares NASDAQ:OPTH	USA	$5.79 Million
Nukkleus Inc NASDAQ:NUKK	USA	$43.71 Million
Turiya Bhd KLSE:4359	Malaysia	RM35.15 Million
Intrasense PA:ALINS	France	€14.45 Million
Starr Peak Exploration Ltd V:STE	Canada	CA$2.91 Million
Keynote Financial Services Limited NSE:KEYFINSERV	India	Rs114.13 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Medifron DBT Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Medifron DBT Co. Ltd asset portfolio.

Liquidity & Leverage Metrics

Medifron DBT Co. Ltd Total Liabilities Ratios Explained

Medifron DBT Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	1.01	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.40	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.76	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Medifron DBT Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Medifron DBT Co. Ltd (2014–2024)

The table below shows the annual total liabilities of Medifron DBT Co. Ltd from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩42.92 Billion ≈ $29.08 Million	+127.15%
2023-12-31	₩18.89 Billion ≈ $12.80 Million	-23.39%
2022-12-31	₩24.66 Billion ≈ $16.71 Million	+262.30%
2021-12-31	₩6.81 Billion ≈ $4.61 Million	-64.84%
2020-12-31	₩19.36 Billion ≈ $13.12 Million	+994.02%
2019-12-31	₩1.77 Billion ≈ $1.20 Million	-25.45%
2018-12-31	₩2.37 Billion ≈ $1.61 Million	+58.92%
2017-12-31	₩1.49 Billion ≈ $1.01 Million	-31.47%
2016-12-31	₩2.18 Billion ≈ $1.48 Million	-69.04%
2015-12-31	₩7.04 Billion ≈ $4.77 Million	+356.92%
2014-12-31	₩1.54 Billion ≈ $1.04 Million	--

About Medifron DBT Co. Ltd

KQ:065650 Korea Biotechnology

Market Cap

$12.64 Million

₩18.64 Billion KRW

Market Cap Rank

#26305 Global

#1980 in Korea

Share Price

₩1401.00

Change (1 day)

+0.00%

52-Week Range

₩1337.00 - ₩3265.00

All Time High

₩8800.00